DK0845007T3 - Farmaceutisk præparat indeholdende interferon-gamma hæmmere - Google Patents

Farmaceutisk præparat indeholdende interferon-gamma hæmmere

Info

Publication number
DK0845007T3
DK0845007T3 DK96927141T DK96927141T DK0845007T3 DK 0845007 T3 DK0845007 T3 DK 0845007T3 DK 96927141 T DK96927141 T DK 96927141T DK 96927141 T DK96927141 T DK 96927141T DK 0845007 T3 DK0845007 T3 DK 0845007T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
preparation containing
containing interferon
gamma inhibitors
gamma
Prior art date
Application number
DK96927141T
Other languages
Danish (da)
English (en)
Inventor
William James Ferguson Mark
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DK0845007T3 publication Critical patent/DK0845007T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK96927141T 1995-08-18 1996-08-09 Farmaceutisk præparat indeholdende interferon-gamma hæmmere DK0845007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
PCT/GB1996/001949 WO1997007136A2 (en) 1995-08-18 1996-08-09 Pharmaceutical composition containing inhibitors of interferon-gamma

Publications (1)

Publication Number Publication Date
DK0845007T3 true DK0845007T3 (da) 2001-12-17

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96927141T DK0845007T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat indeholdende interferon-gamma hæmmere
DK99202497T DK0972521T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99202497T DK0972521T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer

Country Status (12)

Country Link
EP (2) EP0845007B1 (enExample)
JP (2) JP4070809B2 (enExample)
AT (2) ATE208402T1 (enExample)
AU (1) AU713809B2 (enExample)
CA (1) CA2229590C (enExample)
DE (2) DE69626050T2 (enExample)
DK (2) DK0845007T3 (enExample)
ES (2) ES2192018T3 (enExample)
GB (1) GB2304342A (enExample)
PT (2) PT845007E (enExample)
WO (1) WO1997007136A2 (enExample)
ZA (1) ZA966953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1336654A1 (en) 1998-12-09 2003-08-20 Protein Design Labs, Inc. Method of treating psoriasis using anti-gamma interferon antibody
EP1180037A2 (en) * 1999-05-26 2002-02-20 The Brigham and Women's Hospital Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
DE3773387D1 (de) * 1986-06-17 1991-10-31 Biogen Inc Kombination von gammainterferonen und antientzuendungsmitteln oder antipyretischen mitteln zur behandlung von krankheiten.
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
SG43205A1 (en) * 1988-12-19 1997-10-17 American Cyanamid Co A method for the treatment of endotoxic shock in a mammal
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
DE69024398T2 (de) * 1989-04-19 1996-06-13 Hoffmann La Roche Auflösbare Interferon-gamma-Rezeptoren sowie Verfahren zu deren Herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ZA917669B (en) * 1990-09-27 1992-08-26 Schering Corp Antagonists of human gamma interferon
EP0526630A4 (en) * 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
CA2149785A1 (en) * 1992-11-20 1994-06-09 Gail F. Seelig Antagonists of human gamma interferon
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
EP0845007A2 (en) 1998-06-03
ATE231728T1 (de) 2003-02-15
ZA966953B (en) 1998-02-16
EP0845007B1 (en) 2001-11-07
ATE208402T1 (de) 2001-11-15
PT845007E (pt) 2002-03-28
JP4070809B2 (ja) 2008-04-02
JPH11511160A (ja) 1999-09-28
WO1997007136A3 (en) 1997-08-21
DK0972521T3 (da) 2003-05-05
CA2229590C (en) 2010-10-12
JP4616291B2 (ja) 2011-01-19
JP2007119497A (ja) 2007-05-17
ES2192018T3 (es) 2003-09-16
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
GB9516967D0 (en) 1995-10-18
WO1997007136A2 (en) 1997-02-27
AU6707196A (en) 1997-03-12
ES2164911T3 (es) 2002-03-01
HK1023516A1 (en) 2000-09-15
PT972521E (pt) 2003-06-30
CA2229590A1 (en) 1997-02-27
DE69626050T2 (de) 2004-01-22
AU713809B2 (en) 1999-12-09
DE69626050D1 (de) 2003-03-06
EP0972521A1 (en) 2000-01-19
EP0972521B1 (en) 2003-01-29
GB2304342A (en) 1997-03-19

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI973039A7 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU7486081A (en) Pharmaceutical compositions using amino acids for promoting healing of wounds
DK0845007T3 (da) Farmaceutisk præparat indeholdende interferon-gamma hæmmere
DE60006558D1 (de) Stabile lösung von calcitriol zum verpacken in phiolen
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
DE69626987D1 (de) Pharmaceutische komposition
IT8821634A0 (it) Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
DK0425109T3 (da) 3-substitueret-2-oxindolderivater som inhibitorer for interleukin-1-biosyntese
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
ECSP993298A (es) Moduladores de ccr5
GR1001368B (el) Φαρμακευτικοί φορείς.